JP2024520421A - 腎臓活性融合タンパク質及びそれを使用する治療方法 - Google Patents

腎臓活性融合タンパク質及びそれを使用する治療方法 Download PDF

Info

Publication number
JP2024520421A
JP2024520421A JP2023572788A JP2023572788A JP2024520421A JP 2024520421 A JP2024520421 A JP 2024520421A JP 2023572788 A JP2023572788 A JP 2023572788A JP 2023572788 A JP2023572788 A JP 2023572788A JP 2024520421 A JP2024520421 A JP 2024520421A
Authority
JP
Japan
Prior art keywords
compound
fusion protein
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520421A5 (https=
Inventor
キース ブシャール，
ジェフリー ウィリアム ハンター，
ブルース エー． ジュニア アンドリアン，
ソン－クォン キム，
ジュリアン チャンドラー，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority claimed from PCT/US2022/030658 external-priority patent/WO2022251168A1/en
Publication of JP2024520421A publication Critical patent/JP2024520421A/ja
Priority to JP2025086967A priority Critical patent/JP2025116068A/ja
Publication of JP2024520421A5 publication Critical patent/JP2024520421A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
JP2023572788A 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法 Pending JP2024520421A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086967A JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192835P 2021-05-25 2021-05-25
US63/192,835 2021-05-25
PCT/US2022/030658 WO2022251168A1 (en) 2021-05-25 2022-05-24 Kidney active fusion proteins and methods of treatment using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086967A Division JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Publications (2)

Publication Number Publication Date
JP2024520421A true JP2024520421A (ja) 2024-05-24
JP2024520421A5 JP2024520421A5 (https=) 2025-06-04

Family

ID=84178944

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572788A Pending JP2024520421A (ja) 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Country Status (10)

Country Link
US (1) US20240262877A1 (https=)
EP (1) EP4347666A4 (https=)
JP (2) JP2024520421A (https=)
KR (1) KR20240013770A (https=)
CN (1) CN117396519A (https=)
AU (1) AU2022283254A1 (https=)
BR (1) BR112023024627A2 (https=)
CA (1) CA3177162A1 (https=)
IL (1) IL308754A (https=)
MX (1) MX2023014037A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301713A (en) * 2020-10-05 2023-05-01 Alexion Pharma Inc Methods for treating dermatomyositis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527115A (ja) * 2000-03-13 2003-09-16 セント ビンセンツ ホスピタル 新規のｈ因子関連タンパク質５及びその抗体
JP2013520979A (ja) * 2010-03-05 2013-06-10 リグショスピタレト 補体活性化のキメラ抑制分子
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
CA2920293A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527115A (ja) * 2000-03-13 2003-09-16 セント ビンセンツ ホスピタル 新規のｈ因子関連タンパク質５及びその抗体
JP2013520979A (ja) * 2010-03-05 2013-06-10 リグショスピタレト 補体活性化のキメラ抑制分子
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILMORE C. ALYSSA ET AL.: "Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and witho", KIDNEY INTERNATIONAL, vol. 99, JPN6026011025, 28 October 2020 (2020-10-28), pages 396 - 404, ISSN: 0005820710 *
HELLWAGE JENS ET AL.: "The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor", BIOCHEM. J., vol. 326, JPN6026011024, 1997, pages 321 - 327, ISSN: 0005820709 *

Also Published As

Publication number Publication date
JP2025116068A (ja) 2025-08-07
IL308754A (en) 2024-01-01
EP4347666A1 (en) 2024-04-10
CN117396519A (zh) 2024-01-12
EP4347666A4 (en) 2025-07-16
BR112023024627A2 (pt) 2024-02-20
AU2022283254A9 (en) 2023-12-07
KR20240013770A (ko) 2024-01-30
US20240262877A1 (en) 2024-08-08
CA3177162A1 (en) 2022-11-25
AU2022283254A1 (en) 2023-11-30
MX2023014037A (es) 2024-01-15

Similar Documents

Publication Publication Date Title
JP7685737B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
US20220009979A1 (en) Fusion proteins and methods of treating complement dysregulation using the same
JP2023133564A (ja) アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
JP5564268B2 (ja) 成長因子と結合する融合タンパク質
KR101844596B1 (ko) 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
JP2014522641A (ja) リラキシン融合ポリペプチドおよびその使用
JP2015505843A (ja) 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
CA2849705A1 (en) Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CN106687478A (zh) 新的抗人Tie‑2抗体
JP2025116068A (ja) 腎臓活性融合タンパク質及びそれを使用する治療方法
US20240254177A1 (en) COMPLEMENT FACTOR H AND Fc BINDING DOMAIN FUSION PROTEINS
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
AU2012358248B2 (en) Serum amyloid P-antibody fusion proteins
WO2022251168A9 (en) Kidney active fusion proteins and methods of treatment using the same
EA053282B1 (ru) Активные в почках слитые белки и способы лечения с их применением
WO2021154216A1 (en) Fusion proteins and methods of treating complement dysregulation using the same
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
KR20210088571A (ko) 펩티드의 혈중 동태 개선 방법
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
HK1234078B (zh) 新的抗人tie-2抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260319